StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30195% above fair value
$121.40−2.62 (-2.11%)

Close on Nov 20, 2026Market cap $7.86BP/E 117.9Yield –

Protagonist Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Protagonist Therapeutics

Protagonist Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Protagonist Therapeutics figures

See a number that looks wrong?